SITAGLIPTINA 25 mg Film-Coated Tablets
How to use SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS
Translated with AI
This page provides general information and does not replace a doctor’s consultation. Always consult a doctor before taking any medication. Seek urgent medical care if symptoms are severe.
Show originalContents of the leaflet
Introduction
Package Leaflet: Information for the User
Sitagliptin Aurovitas 25 mg film-coated tablets EFG
Sitagliptin Aurovitas 50 mg film-coated tablets EFG
Sitagliptin Aurovitas 100 mg film-coated tablets EFG
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
- Keep this leaflet, you may need to read it again.
- If you have any further questions, ask your doctor or pharmacist.
- This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours.
- If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.
Contents of the pack
- What is Sitagliptin Aurovitas and what is it used for
- What you need to know before you take Sitagliptin Aurovitas
- How to take Sitagliptin Aurovitas
- Possible side effects
- Storage of Sitagliptin Aurovitas
- Contents of the pack and other information
1. What is Sitagliptin Aurovitas and what is it used for
Sitagliptin Aurovitas contains the active substance sitagliptin, which belongs to a class of medicines called DPP-4 inhibitors (dipeptidyl peptidase-4 inhibitors) that reduce blood sugar levels in adult patients with type 2 diabetes mellitus.
This medicine helps to increase the amount of insulin produced after a meal and decreases the amount of sugar produced by the body.
Your doctor has prescribed this medicine to help you reduce your blood sugar level, which is too high due to your type 2 diabetes. This medicine can be used alone or in combination with other medicines (insulin, metformin, sulfonylureas, or glitazones) that reduce blood sugar levels, which you may already be taking for your diabetes, along with your diet and exercise program.
What is type 2 diabetes?
Type 2 diabetes is a condition where your body does not produce enough insulin, and the insulin it does produce does not work as well as it should. Your body may also produce too much sugar. When this happens, sugar (glucose) builds up in the blood. This can lead to serious medical problems, such as heart disease, kidney disease, blindness, and amputation.
2. What you need to know before you take Sitagliptin Aurovitas
Do not takeSitagliptinAurovitas
- If you are allergic to sitagliptin or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Consult your doctor or pharmacist before starting to take sitagliptin.
There have been reports of pancreatitis (inflammation of the pancreas) in patients treated with sitagliptin (see section 4).
If you notice blisters on your skin, it may be a sign of a disease called bullous pemphigoid. Your doctor may ask you to stop taking sitagliptin.
Tell your doctor if you have or have had:
- a disease of the pancreas (such as pancreatitis).
- gallstones, alcohol dependence, or very high levels of triglycerides (a type of fat) in the blood. These medical problems may increase your risk of developing pancreatitis (see section 4).
- type 1 diabetes.
- diabetic ketoacidosis (a complication of diabetes that causes high blood sugar levels, rapid weight loss, nausea, or vomiting).
- any kidney problem you have now or have had in the past.
- an allergic reaction to sitagliptin (see section 4).
It is unlikely that this medicine will cause low blood sugar because it does not work when your blood sugar levels are low. However, when this medicine is used in combination with a medicine that contains a sulfonylurea or with insulin, low blood sugar (hypoglycemia) may occur. Your doctor may reduce the dose of your sulfonylurea or insulin medicine.
Children and adolescents
Children and adolescents under 18 years of age should not use this medicine. It is not effective in children and adolescents aged between 10 and 17 years. It is not known if this medicine is safe and effective when used in children under 10 years of age.
Other medicines andSitagliptinAurovitas
Tell your doctor or pharmacist if you are taking, have recently taken, or might take any other medicines.
In particular, tell your doctor if you are taking digoxin (a medicine used to treat irregular heartbeat and other heart problems). Your doctor may need to check the level of digoxin in your blood if you are taking sitagliptin.
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
Do not take this medicine during pregnancy.
It is not known if this medicine passes into breast milk. Do not take this medicine if you are breastfeeding or plan to breastfeed.
Driving and using machines
The effect of this medicine on your ability to drive or use machines is negligible. However, dizziness and somnolence have been reported, which may affect your ability to drive or use machines.
Also, taking this medicine with sulfonylurea or insulin medicines may cause low blood sugar (hypoglycemia), which may affect your ability to drive or use machines or work without a safe support.
SitagliptinAurovitas contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; this is essentially "sodium-free".
3. How to take Sitagliptin Aurovitas
Take this medicine exactly as your doctor has told you. If you are not sure, ask your doctor or pharmacist.
The recommended dose is:
- one 100 mg film-coated tablet.
- once a day.
- by mouth.
If you have kidney problems, your doctor may prescribe lower doses (such as 25 mg or 50 mg).
You can take this medicine with or without food and drinks.
Your doctor may prescribe this medicine alone or with other medicines that also reduce blood sugar levels.
Diet and exercise may help your body use sugar better. It is important that you follow the diet and exercise recommended by your doctor while taking sitagliptin.
If you take moreSitagliptinAurovitas than you should
If you take more of this medicine than you should, contact your doctor immediately.
In case of overdose or accidental ingestion, consult your doctor or pharmacist immediately or call the Toxicology Information Service, phone 91 562 04 20, indicating the medicine and the amount taken.
If you forget to takeSitagliptinAurovitas
If you forget a dose, take it as soon as you remember. If you do not remember until the time of your next dose, then skip the missed dose and continue with your regular schedule. Do not take a double dose to make up for missed doses.
If you stop taking Sitagliptin Aurovitas
Continue taking this medicine while your doctor tells you to, so it can continue to help control your blood sugar levels. Do not stop taking this medicine without first consulting your doctor.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
4. Possible side effects
Like all medicines, this medicine can cause side effects, although not everybody gets them.
STOP taking sitagliptin and contact a doctor immediatelyif you notice any of the following serious side effects:
- Severe and persistent abdominal pain (in the stomach area) that may radiate to the back, with or without nausea and vomiting, as these may be signs of pancreatitis.
If you have a severe allergic reaction (frequency not known), including skin rash, hives, blisters on the skin/peeling of the skin, and swelling of the face, lips, tongue, and throat that may cause difficulty breathing or swallowing, stop taking this medicine and consult your doctor immediately. Your doctor will prescribe a medicine to treat the allergic reaction and change your medicine for diabetes treatment.
Some patients experienced the following side effects after adding sitagliptin to their treatment with metformin:
Common (may affect up to 1 in 10 people): low blood sugar, nausea, flatulence, vomiting.
Uncommon (may affect up to 1 in 100 people): stomach pain, diarrhea, constipation, somnolence.
Some patients experienced different types of stomach discomfort when starting the combination of sitagliptin and metformin together (frequency classified as common).
Some patients experienced the following side effects while taking sitagliptin in combination with a sulfonylurea and metformin:
Very common (may affect more than 1 in 10 people): low blood sugar.
Common: constipation.
Some patients experienced the following side effects while taking sitagliptin and pioglitazone:
Common: flatulence, swelling of hands or feet.
Some patients experienced the following side effects while taking sitagliptin and pioglitazone and metformin:
Common: swelling of hands or feet.
Some patients experienced the following side effects while taking sitagliptin in combination with insulin (with or without metformin):
Common: flu.
Uncommon: dry mouth.
Some patients experienced the following side effects while taking sitagliptin alone during clinical trials or during use after approval alone and/or with other diabetes medicines:
Common: low blood sugar, headache, upper respiratory tract infection, nasal congestion or runny nose, and sore throat, arthrosis, pain in the arm or leg.
Uncommon: dizziness, constipation, itching.
Rare: reduction in the number of platelets.
Frequency not known: kidney problems (which may require dialysis), vomiting, joint pain, muscle pain, back pain, interstitial lung disease, bullous pemphigoid (a type of blister on the skin).
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines and Healthcare Products Agency (AEMPS) at www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.
5. Storage of Sitagliptin Aurovitas
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton, bottle, and blister after EXP. The expiry date is the last day of the month shown.
This medicine does not require any special storage conditions.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
6. Contents of the pack and other information
Composition ofSitagliptinAurovitas
- The active substance is sitagliptin.
Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 25 mg of sitagliptin.
Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 50 mg of sitagliptin.
Each film-coated tablet contains sitagliptin hydrochloride monohydrate equivalent to 100 mg of sitagliptin.
- The other ingredients are:
Core of the tablet:microcrystalline cellulose (grade 102), calcium hydrogen phosphate, sodium croscarmellose, magnesium stearate, and sodium stearyl fumarate.
Coating of the tablet:polyvinyl alcohol (E1203), titanium dioxide (E171), macrogol 3350 (E1521), talc (E553b), yellow iron oxide (E172), and red iron oxide (E172).
Appearance of the product and contents of the pack
Sitagliptin Aurovitas 25 mg film-coated tablets EFG[approximate size 6.2 mm]
Film-coated tablets are pink, round, biconvex, with the marks "SG" on one face and "25" on the other.
Sitagliptin Aurovitas 50 mg film-coated tablets EFG[approximate size 8 mm]
Film-coated tablets are light beige, round, biconvex, with the marks "SG" on one face and "50" on the other.
Sitagliptin Aurovitas 100 mg film-coated tablets EFG[approximate size 9.9 mm]
Film-coated tablets are beige, round, biconvex, with the marks "SG" on one face and "100" on the other.
Sitagliptin Aurovitas 25 mg, 50 mg, and 100 mg film-coated tablets EFG are available in blister packs and HDPE bottles.
Package sizes:
Blister:10, 14, 28, 30, 56, 60, 84, 90, 98, 100, 112, and 120 film-coated tablets.
HDPE bottles:30, 500, and 1,000 film-coated tablets.
Not all pack sizes may be marketed.
Marketing authorization holder and manufacturer
Marketing authorization holder
Aurovitas Spain, S.A.U.
Avda. de Burgos, 16-D
28036 Madrid
Spain
Phone: 91 630 86 45
Manufacturer
APL Swift Services (Malta) Limited
HF26, Hal Far Industrial Estate, Hal Far
Birzebbugia, BBG 3000
Malta
Or
Generis Farmacêutica, S.A.
Rua João de Deus, 19
2700-487 Amadora
Portugal
Or
Arrow Génériques
26 Avenue Tony Garnier
69007 Lyon
France
This medicine is authorized in the Member States of the European Economic Area under the following names:
Germany: Sitagliptin PUREN 25 mg/50 mg/100 mg Filmtabletten
Belgium: Sitagliptine AB 25 mg/50 mg/100 mg filmomhulde tabletten / comprimés pelliculés / Filmtabletten
Spain: Sitagliptina Aurovitas 25 mg/50 mg/100 mg comprimidos recubiertos con película EFG
France: Sitagliptine Arrow 50 mg/100 mg comprimé pelliculé
Netherlands: Sitagliptine Aurobindo 25 mg/50 mg/100 mg, filmomhulde tabletten
Poland: Sitagliptin Aurovitas
Romania: Sitagliptina Aurobindo 50 mg/100 mg comprimate filmate
Date of last revision of this leaflet: May 2022
Detailed information on this medicine is available on the website of the Spanish Agency for Medicines and Healthcare Products (AEMPS) (http://www.aemps.gob.es/).
- Country of registration
- Dosage formTABLET, 25 mg
- ATC codeA10BH01
- Average pharmacy price6.63 EUR
- Active substance
- Prescription requiredYes
- Manufacturer
- CompositionCROSCARMELOSA SODICA (3 mg mg), FUMARATO DE ESTEARILO Y SODIO (2 mg mg)
- This information is for reference only and does not constitute medical advice. Always consult a doctor before taking any medication. Oladoctor is not responsible for medical decisions based on this content.
- Alternatives to SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETSDosage form: TABLET, 100 mgActive substance: sitagliptinManufacturer: Laboratorios Alter S.A.Prescription requiredDosage form: TABLET, 25 mgActive substance: sitagliptinManufacturer: Laboratorios Alter S.A.Prescription requiredDosage form: TABLET, 50 mgActive substance: sitagliptinManufacturer: Laboratorios Alter S.A.Prescription required
Online doctors for SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS
Discuss questions about SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS, including use, safety considerations and prescription review, subject to medical assessment and local regulations.
Book a video appointment 
Get SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS Prescription Online
Fill in a 2-min form
Tell us your symptoms, history, and what medicine you're requesting.
Pick a doctor or let us assign
Choose a specialist or we'll match you with the next available doctor.
Doctor reviews your case
Usually within 30 minutes. They may ask follow-up questions via chat.
Collect from any pharmacy
Electronic prescription sent to your email — valid across Spain.
Frequently Asked Questions
Is a prescription required for SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS?
SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS requires a prescription in Spain. You can check with a doctor online whether this medicine may be appropriate for your situation.
What is the active substance in SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS?
The active ingredient in SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS is sitagliptin. This information helps identify medicines with the same composition but different brand names.
How much does SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS cost in pharmacies?
The average pharmacy price for SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS is around 6.63 EUR. Prices may vary depending on the manufacturer and dosage form.
Who manufactures SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS?
SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS is manufactured by Aurovitas Spain, S.A.U.. Pharmacy brands and packaging may differ depending on the distributor.
Which doctors can assess the use of SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS online?
Doctors such as Family doctors, Psychiatrists, Dermatologists, Cardiologists, Endocrinologists, Gastroenterologists, Pulmonologists, Nephrologists, Rheumatologists, Hematologists, Infectious disease physicians, Allergists, Geriatricians, Paediatricians, Oncologists may assess whether SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS is appropriate, depending on your situation and local regulations. You can book an online consultation to discuss your symptoms and possible next steps.
How to buy SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS in Spain?
Spain has a well-developed healthcare infrastructure across major cities such as Madrid, Barcelona, Valencia, and Seville. Pharmacies are widely available and operate under strict regulations, ensuring access to prescribed medications.
You can buy SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS in Madrid, Barcelona, Seville, or Valencia at any local pharmacy with a valid prescription.
To obtain a prescription, you can use Oladoctor:
What are the alternatives to SITAGLIPTIN Aurovitas 25 mg FILM-COATED TABLETS?
Other medicines with the same active substance (sitagliptin) include DISIT 100 mg FILM-COATED TABLETS, DISIT 25 mg FILM-COATED TABLETS, DISIT 50 mg FILM-COATED TABLETS. These may have different brand names or formulations but contain the same therapeutic ingredient. Always consult a doctor before switching or starting a new medicine.
